The purpose of this study is to compare two different creams (5-fluorouracil, known as Efudix, and calcipotriol, known as Dovonex) to see which one works better when used before Photodynamic Therapy (PDT) to treat sun-damaged skin on the scalp (called actinic keratoses).
PDT is often used on its own to treat these spots, but it doesn't always remove them completely. Using Efudix or Dovonex before PDT might improve the results, but we don't yet know which is better.
The main questions are -
1. Is efudix or dovonex better at treating actinic keratoses when used prior to PDT
2. Is efudix or dovonex more tolerable for patients?
Participants will be randomised to treat their scalp with efudix or dovonex for seven days prior to their first PDT treatment. They will be reviewed on day 7, prior to starting PDT, and again a week later when they present for their second PDT treatment.
During follow up, patients will be reviewed at 28 days, 3, 6, 9, and 12 months after treatment.
At each of these visits, the number of actinic keratoses will be counted, graded, mapped and photographed to allow assessment of improvement before and after treatment.

开始日期2025-01-01

申办/合作机构

St. Vincent's University Hospital

NCT06499415 / Recruiting临床4期IIT

Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis: a Multicentre Randomized Controlled Clinical Trial

5-Fluorouracil (5FU) is proven to be the most effective therapy in field directed treatment for AK, with Jansen et al. reporting a 1-year probability of treatment success of 74.7%. However, treatment with 5FU is associated with side effects, like erythema, itching, a burning sensation and crusting, and a burdensome dosing regimen of twice daily application for four weeks. This long treatment duration in combination with side-effects and overall lifestyle adjustments during treatment can be the reason for poor adherence and premature termination, and it can also lead to future refusal of 5FU therapy. Therefore, room for improvement lies in increasing the tolerability, in terms of side effects or treatment duration, while maintaining the efficacy of 5FU in the treatment of AK.
Addition therapy, which can shorten the duration of treatment, might be the key to success. Calcipotriol (CAL) enhances thymic stromal lymphopoietin (TSLP), an epithelium-derived cytokine, which promotes antitumor immunity. Therefore, it is known to have a synergistic effect when combined with 5FU in the treatment of AK. This suggests that short-term treatment with 5FU-CAL is effective and provides the opportunity to shorten duration of treatment, thereby improving tolerability of treatment and full adherence to the treatment regimen.
However, no study compared 5FU-CAL combination therapy with standard 5FU treatment for a duration of 28 days. This study aims to evaluate whether a short course of combination therapy with 5FU-CAL is non-inferior to a full course of 5FU monotherapy with respect to the 1-year probability of treatment success.

开始日期2024-09-04

申办/合作机构-

NCT05699603 / Recruiting临床2期IIT

Phase IIA, Single-Arm, Open- Label, Clinical Trial of Calcipotriene Plus 5-fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients

This phase IIA study evaluates the effects of calcipotriene plus 5- fluorouracil immunotherapy for skin cancer prevention in organ transplant recipients. Precancerous skin lesions, actinic keratoses (AK), may put organ transplant recipients at higher than average risk of developing skin cancer. Topical calcipotriene is a form of vitamin D and is used to treat psoriasis and topical 5- fluorouracil is a chemotherapy agent applied to the skin. The combination of calcipotriene plus 5- fluorouracil topical cream, which activates the immune cells against cancer, may help prevent skin cancer in organ transplant recipients who have precancerous skin lesions.

开始日期2024-07-02

申办/合作机构

University of Arizona

[+1]

100 项与卡泊三醇相关的临床结果

登录后查看更多信息

100 项与卡泊三醇相关的转化医学

登录后查看更多信息

100 项与卡泊三醇相关的专利（医药）

登录后查看更多信息

1,565

项与卡泊三醇相关的文献（医药）

2024-12-31·Journal of Dermatological Treatment

Comparison of various excimer laser (EL) combination therapies for vitiligo: a systematic review and network meta-analysis

Review

作者: Wang, XinYue ; Shi, Lei ; Mu, ZengYi ; Wang, YaPing ; Li, XinHong ; Hu, Yue ; Li, ChanXiu ; Sun, Xiao

AIMThis study aimed to compare the efficacy and safety of excimer laser (EL)-based combination regimens in improving repigmentation.METHODSA comprehensive search was conducted in PubMed, Web of Science, Cochrane Library, and Embase on July 1, 2023, to include randomized controlled trials of EL combination treatments for vitiligo that met the criteria. The primary outcome measure was a repigmentation rate ≥ 75%, and the secondary outcome measures were a repigmentation rate of ≤ 25% and adverse events.RESULTSEleven studies involving 348 patients were included. Network Meta-Analysis showed that EL combined with antioxidants (SUCRA = 98.8%), EL combined with calcipotriol (SUCRA = 59.8%) and EL combined with tacalcitol (SUCRA = 59.6%) were the three optimal interventions achieving repigmentation rates ≥ 75%. EL alone (SUCRA = 77.6%), EL combined with tacalcitol (SUCRA = 61.7%) and EL combined with antioxidants (SUCRA = 57.2%) were the three interventions with the highest rates of treatment failure. Adverse events in all groups mainly included erythema, burning sensation and hyperpigmentation. Based on the results of the current study, EL combination therapies were safe with mild adverse events.CONCLUSIONEL combined with antioxidants was the preferred regimen for vitiligo, whereas EL alone was the regimen with the highest rate of treatment failure in vitiligo.

2024-12-31·Journal of Dermatological Treatment

Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey

Article

作者: Galván, Jordi ; López Estebaranz, José Luis ; Kurzen, Hjalmar

BACKGROUNDPsoriasis significantly impacts patients' quality of life (QoL). Dissatisfaction and non-adherence are major barriers associated with topical treatments. A cream based on the polyaphron dispersion (PAD) Technology containing a fixed-dose of calcipotriol (CAL) and betamethasone dipropionate (BDP) was designed for a patient-friendly psoriasis management. The CAL/BDP PAD-cream demonstrated efficacy, convenience, and safety/tolerability in clinical trials.OBJECTIVESThis research assesses the real-world use, perception, satisfaction, and adherence of CAL/BDP PAD-cream among plaque psoriasis patients.METHODSBetween September-November 2023, psoriasis patients from Spain and Germany using or having used CAL/BDP PAD-cream for >2 weeks were recruited via Wefight network to complete a 30-questions online survey. Anonymized results were pooled for descriptive statistical analysis.RESULTSThe survey was completed by 129 patients (mean age: 43 years; 66% females; mean psoriasis duration: 12 years). Most patients (93%) were satisfied with CAL/BDP PAD-cream. The 66% reported high adherence (visual analogue scale 80-100) and 91% preferred CAL/BDP PAD-cream to their previous topical(s). Patients highlighted its ease/convenience of application, tolerability, and lack of itching/burning.CONCLUSIONSPsoriasis patients treated with CAL/BDP PAD-cream in a real-world setting show high satisfaction, good adherence, and a positive perception of the product, suggesting that favorable outcomes observed in clinical trials translate to real clinical practice.

2024-12-01·Current Computer-Aided Drug Design

Network Pharmacology, Molecular Docking and Experimental Verification Revealing the Mechanism of Fule Cream against Childhood Atopic Dermatitis

Article

作者: Qi, Yuenan ; Gao, Ying ; Liu, Chang ; Liu, Yuxin ; Guan, Jing ; Liu, Yi ; Ou, Ling ; Zhang, Jianmin ; Lv, Xiaoxi

Background:The Fule Cream (FLC) is an herbal formula widely used for the treatment of pediatric atopic dermatitis (AD), however, the main active components and functional mechanisms of FLC remain unclear. This study performed an initial exploration of the potential acting mechanisms of FLC in childhood AD treatment through analyses of an AD mouse model using network pharmacology, molecular docking technology, and RNA-seq analysis.Materials and Methods:The main bioactive ingredients and potential targets of FLC were collected from the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) and SwissTargetPrediction databases. An herb-compound-target network was built using Cytoscape 3.7.2. The disease targets of pediatric AD were searched in the DisGeNET, Therapeutic Target Database (TTD), OMIM, DrugBank and GeneCards databases. The overlapping targets between the active compounds and the disease were imported into the STRING database for the construction of the protein-protein interaction (PPI) network. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of the intersection targets were performed, and molecular docking verification of the core compounds and targets was then performed using AutoDock Vina 1.1.2. The AD mouse model for experimental verification was induced by MC903.Results:The herb-compound-target network included 415 nodes and 1990 edges. Quercetin, luteolin, beta-sitosterol, wogonin, ursolic acid, apigenin, stigmasterol, kaempferol, sitogluside and myricetin were key nodes. The targets with higher degree values were IL-4, IL-10, IL-1α, IL-1β, TNFα, CXCL8, CCL2, CXCL10, CSF2, and IL-6. GO enrichment and KEGG analyses illustrated that important biological functions involved response to extracellular stimulus, regulation of cell adhesion and migration, inflammatory response, cellular response to cytokine stimulus, and cytokine receptor binding. The signaling pathways in the FLC treatment of pediatric AD mainly involve the PI3K-Akt signaling pathway, cytokine‒cytokine receptor interaction, chemokine signaling pathway, TNF signaling pathway, and NF-κB signaling pathway. The binding energy scores of the compounds and targets indicate a good binding activity. Luteolin, quercetin, and kaempferol showed a strong binding activity with TNFα and IL-4.Conclusion:This study illustrates the main bioactive components and potential mechanisms of FLC in the treatment of childhood AD, and provides a basis and reference for subsequent exploration.

项与卡泊三醇相关的新闻（医药）

2024-11-15

·PRNewswire

Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada

MALVERN, Pa., Nov. 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream (calcipotriene and betamethasone dipropionate) in Canada through Endo's subsidiary Paladin Pharma Inc. "We look forward to working with MC2 to make Wynzora® Cream available to Canadians who suffer from plaque psoriasis," said Livio Di Francesco, Vice President and General Manager of Paladin. "If approved by Health Canada, Wynzora® Cream's unique formulation and clinical profile will offer patients a new treatment option designed for convenience of use in daily routines." "Paladin has an experienced and dedicated team, and we're pleased to work with them to introduce Wynzora® Cream in Canada," said Jesper J. Lange, Chief Executive Officer, MC2 Therapeutics. "The agreement aligns with our strategy to make Wynzora® Cream available to as many patients suffering from plaque psoriasis as possible globally." Wynzora® Cream was approved in the US by the FDA on July 20, 2020 and launched in Europe on February 18, 2022. About Wynzora® Cream Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis, in adults. Its dual mode of action is targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product. Wynzora® Cream is uniquely enabled by MC2's formulation and drug delivery system PAD Technology™, allowing a convenient-to-use aqueous formulation. About Endo and Paladin Pharma Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at or connect with us on LinkedIn. Paladin Pharma Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing, medical and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies. Paladin is an operating company of Endo, Inc. For more information, visit . About MC2 Therapeutics () MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation. Its pioneering approach in immunology is anchored in a deep understanding of skin biology, clinical expertise and cross-silo thinking. Besides Wynzora® Cream, MC2 has a pipeline that includes two first-in-class drug candidates, both in Phase 2 clinical development. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the statements by Messrs. Di Francesco and Lange and any statements relating to product development and commercialization, treatment options and therapies, regulatory approval, efficacy and product availability. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, unfavorable or delayed regulatory review, uncertainties in and the timing for regulatory approval, changes in competitive, market or regulatory conditions, and consumer and physician acceptance of current and new products. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in Endo's press releases and in its public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-Q and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A. SOURCE Endo, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准引进/卖出临床2期

2024-11-11

·CPHI制药在线

采购直通车 | 制药行业的采购狂欢，40000+原料药产品等你来选！

制药在线精心策划的“采购直通车原料药专场”活动，已于近日盛大开启！这不仅是一场行业盛会，更是一次不容错过的商机！采购直通车是制药在线整合线上线下资源，精心打造的系列活动，旨在为制药行业的买卖双方提供高效、直接的对接平台。活动聚焦制药原料、原料药设备、精细化工、制药包装设备、实验室设备等关键领域，汇聚国内外知名制药企业，展示丰富多样的产品，促进供需双方深度交流与合作。每一次采购直通车活动，都是一次洞察行业趋势、解锁新商机的绝佳机会！作为“采购直通车”系列活动的首站，原料药专场无疑是最受瞩目的焦点，超过1300家国内外制药企业积极参与，产品展示超过40,000个，覆盖了所有关键领域，只为满足您的多元化需求！还在等什么，赶紧参与吧！扫码了解更多本场热门产品推荐维生素B1盐酸硫铵维生素C 1%生物素氟苯尼考氯霉素甲砜霉素四环素胶囊盐酸米诺环素替加环素青霉素V钾哌拉西林钠阿莫西林依泽麦布普司乐盐酸氨溴索盐酸特比萘芬头孢丙烯头孢噻呋钠扫码发现更多热门产品部分优选企业推荐（排序不分先后）天津中瑞药业股份有限公司天津中瑞药业股份有限公司是一家专业生产化学原料药、药用辅料、食品添加剂的高新技术企业，主要产品包括肌醇烟酸酯、盐酸特拉唑嗪、盐酸法舒地尔、盐酸特拉唑嗪、盐酸多巴胺、硫酸氢氯吡格雷、烟酸、烟酰胺。江西晨阳药业有限公司江西晨阳药业有限公司主要研发、生产销售医药中间体、原料药和其他化学品，目前主要生产产品为加替环合酯(喹啉羧酸乙酯）、加替羧酸（喹啉羧酸）、加替沙星、甲磺酸加替沙星、左氧氟环合酯、左氧氟羧酸、左氧氟沙星、盐酸左氧氟沙星、吡喹酮及其中间体、沙拉沙星、盐酸沙拉沙星及其中间体、盐酸莫西沙星及其中间体等。山东四环药业股份有限公司山东四环药业股份有限公司于2004年成立，是一家从事医药原料研发、生产与销售一体的科技型公司。公司主营产品有苯甲酸阿格列汀及中间体、曲格列汀琥珀酸盐、利格列汀及其中间体、泰诺福韦艾拉酚胺富马酸盐、LCZ696、新利司他、迈瑞替尼甲磺酸盐(AZD-9291)、依鲁替尼、巴瑞克替尼及其中间体、维利帕尼、盐酸头孢甲肟、苄星头孢匹林、4-羟基吡啶、头孢西酮酸及其中间体、头孢特仑酸、α-磺基苯乙酸、萘夫西林及中间体、磺苄西林钠、2-羟基-1-萘甲醛等。西安秦凯生物科技有限公司西安秦凯生物科技有限公司成立于2005年，是一家从事原料药和医药中间体研发、生产、销售的企业。公司现有产品6大类、100余种，主要产品为维生素D衍生物及其中间体、相关杂质。涉及到的维生素D衍生物有：艾地骨化醇、钙泊三醇、骨化三醇、帕立骨化醇、马沙骨化醇、骨化二醇、度骨化醇、阿尔法骨化醇。浙江海正药业股份有限公司海正药业是一家集研产销全价值链、原料药与制剂一体化、多地域发展的综合性制药企业，是全国最大的抗生素、抗肿瘤药物生产基地之一，公司专注于创新药、生物药、仿制药和高端原料药的研发、生产、销售，药品涵盖抗肿瘤、抗感染、心血管、内分泌、免疫抑制、抗抑郁、骨科等十多个治疗领域。石家庄新发化工科技有限公司 NEWPHARM是一家位于中国的活性药物成分（API）供应商，拥有超过25年的行业经验。公司不仅专注于API供应，还提供API材料的合同制造服务，并在拉丁美洲和亚洲市场实现了API产品的商业化。杭州德立化工有限公司杭州德立化工有限公司成立于2005年，专业生产医药原料药、医药中间体和其他化工品的工厂，主要产品包括屈螺酮、去氢孕酮、去氧孕烯、异维A酸、维A酸、阿维A酸、盐酸氨溴索、盐酸溴己新、地奥司明、氨甲环酸、对氯、对胺、酒石酸溴莫尼定等多种原料药和中间体。浙江天台药业股份有限公司浙江天台药业股份有限公司，成立于1998年6月，专业从事盐酸克林霉素、克林霉素磷酸酯和两性霉素B等抗生素、抗真菌系列特色原料药研发、生产及销售和原料药CRO&CDMO业务，是国内外盐酸克林霉素、克林霉素磷酸酯的主要生产商之一。更多优质企业等您来搜... 活动咨询申请入驻：万女士 T：02133392284 E：mili.wan@imsinoexpo.com 采购顾问：姚女士 T：02133392254 E：freya.yao@imsinoexpo.com 扫码查看更多厂家及产品信息您需要的这里都有哦！ END

带量采购

2024-10-01

·医药地理

信达生物1类抗体新药上市申报 | 银屑病治疗市场全景分析

银屑病，也被广泛称为“牛皮癣”，是一种常见的多基因遗传性皮肤疾病，常表现为局限或广泛分布的鳞屑性红斑或斑块。在中国，据不完全统计，银屑病的发病率约为0.47%，约有650万患者。全球范围内，根据2016年世界卫生组织（WHO）的数据，约有1.25亿人受银屑病影响。银屑病不单是一种皮肤病，它还包含全身性的炎症过程，因此被归类为系统性疾病。虽然早期研究一直聚焦于角质形成细胞的作用，但近期的发现表明，活化的T细胞，特别是Th1、Th2和Th17细胞的激活与相互作用，才是银屑病发病的核心机制。得益于这些研究成果，银屑病的治疗实现了突破性进展。特别是生物制剂的应用，它们在靶向治疗银屑病方面取得了显著成就。 9月26日，中国国家药监局药品审评中心（CDE）官网最新公示，信达生物1类新药匹康奇拜单抗注射液上市申请获得受理。匹康奇拜单抗（研发代号：IBI112）是由信达生物研发的一款重组抗白介素23p19亚基（IL-23p19）抗体。在2024年5月，信达生物宣布，该产品在中国中重度斑块状银屑病患者中进行的3期临床研究CLEAR-1中，成功达到了主要终点和所有关键次要终点。研究结果显示，接受匹康奇拜单抗治疗的患者中，有超过80%的受试者在16周治疗后达到了PASI 90（银屑病面积和严重程度指数改善90%以上）。此外，该药物还展现了长期疗效维持和季度给药间隔的优势，即在维持期内，患者可每12周接受一次给药，预计年度给药次数仅需5至6次。生物制品占据抗银屑病用药的主要市场根据PDB药物综合数据库国内全渠道放大数据显示，抗银屑病用药的生物制品市场金额增长迅猛，从2020年的7.79亿元增长至2023年的51.43亿元，以87%的份额占据抗银屑病用药的主要市场。化学药品的市场金额变化趋势较为平缓，基本没有太大的变化，2023年总销售额达到7.96亿元，占比总市场份额的13%。图1：2020-2024（Q1）抗银屑病生物制品市场金额变化趋势数据来源：PDB药物综合数据库-国内全渠道放大数据，中国医药工业信息中心图2：2020-2024（Q1）抗银屑病化学药品市场金额变化趋势数据来源：PDB药物综合数据库-国内全渠道放大数据，中国医药工业信息中心生物制品中的各产品占比情况 2023年，在抗银屑病用药生物制品中，司库奇尤单抗以73.19%的市场份额稳居首位，其总销售额达到了37.64亿元。乌司奴单抗以17.06%的市场份额位居第二，总销售额为8.78亿元。紧随其后的是依奇珠单抗、古塞奇尤单抗、佩索利单抗和抗人IL-8单克隆抗体，这些生物制品在银屑病治疗领域均展现了显著的疗效和市场潜力。随着生物制剂的不断研发和应用，预计银屑病治疗市场将持续扩大，为患者提供更多的治疗选择。图3：2020-2024（Q1）抗银屑病生物制剂产品通用名变化趋势数据来源：PDB药物综合数据库-国内全渠道放大数据，中国医药工业信息中心化学药品中的各产品占比情况 2023年，在抗银屑病用药化学药品中，卡泊三醇以44.75%的市场份额领跑，创下3.56亿元的销售额。卡泊三醇与倍他米松的复方制剂也表现不俗，市场占有率为27.68%，销售额达到2.22亿元。此外，本维莫德、阿维A、他卡西醇等药物也在市场中占有一席之地。图4：2020-2024（Q1）抗银屑病化学药品产品通用名变化趋势数据来源：PDB药物综合数据库-国内全渠道放大数据，中国医药工业信息中心小结抗银屑病用药市场正在快速增长，主要得益于新型生物制剂和药物的不断推出，为患者提供了更多样化的治疗选择。但这一增长同时带来了挑战，包括治疗费用的高昂给患者带来的经济压力、患者依从性问题、市场竞争的加剧、新药市场准入和医保覆盖的复杂性，以及对个体化治疗需求的增加。为了解决这些问题，未来还需要各方面的合作，包括通过临床研究和药物经济学评估来提高药物的可及性和可负担性，同时通过政策改革和市场推广来提高患者的依从性和治疗效果。 END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

上市批准临床3期申请上市

100 项与卡泊三醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01125	卡泊三醇	D05AX02	DB02300

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
寻常性银屑病	日本	Leo Pharma, Inc.	2000-01-18
斑块状银屑病	美国	LEO Pharma A/S	1993-12-29
银屑病	-	Leo Pharma, Inc.	1990-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
银屑病	临床3期	印度	Lipidor AB	2018-10-03
斑块状银屑病	临床3期	印度	Cadila Pharmaceuticals Ltd.	2018-08-20
寻常性银屑病	临床3期	英国	Leo Pharma, Inc.	2008-02-01
寻常性银屑病	临床3期	法国	Leo Pharma, Inc.	2008-02-01
寻常性银屑病	临床3期	加拿大	Leo Pharma, Inc.	2008-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCD2023	N/A	毛发红糠疹一线	-	Methotrexate	(繭蓋鬱鏇積遞獵鏇廠襯) = 獵顧淵構齋鬱窪壓衊糧醖繭憲製醖鹽範齋窪範 (願膚製鑰簾齋蓋膚繭夢 ) 更多	-	2023-07-03
				Topical Calcipotriol	(繭蓋鬱鏇積遞獵鏇廠襯) = 選窪壓衊窪遞鬱鬱鬱製醖繭憲製醖鹽範齋窪範 (願膚製鑰簾齋蓋膚繭夢 ) 更多
phase 3 (EADV2022)	临床3期	斑块状银屑病	796	Calcipotriene and betamethasone dipropionate cream	衊膚齋獵蓋淵壓製遞鏇(餘鬱艱艱齋糧製淵醖廠) = 鏇製窪襯壓襯觸膚襯膚積窪膚製獵夢獵鹽醖齋 (範淵鏇壓鏇鹹繭齋積膚 ) 更多	积极	2022-09-07
				Calcipotriene and betamethasone dipropionate gel	衊膚齋獵蓋淵壓製遞鏇(餘鬱艱艱齋糧製淵醖廠) = 憲鹽觸衊鑰遞齋顧獵願積窪膚製獵夢獵鹽醖齋 (範淵鏇壓鏇鹹繭齋積膚 ) 更多
Pubmed 人工标引	N/A	寻常性银屑病	166	Calcipotriene+LEO90100	(廠鏇觸獵顧製鬱膚遞選) = 窪構遞艱窪艱範膚鏇簾繭觸襯築襯糧網窪獵糧 (獵鏇獵膚簾鬱齋鏇鬱繭, 3.0) 更多	积极	2022-07-18
EADV2022	N/A	斑块状银屑病	-	Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g aerosol foam	膚窪廠衊壓醖壓糧壓簾(鬱糧觸築憲壓淵觸餘鏇) = 餘憲鹽憲鹽壓艱製窪鹽簾網艱選鏇網齋鬱製網 (蓋製願簾簾醖艱鬱齋簾 )	-	2022-05-12
				Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g cream	膚窪廠衊壓醖壓糧壓簾(鬱糧觸築憲壓淵觸餘鏇) = 築鬱鏇網餘衊顧窪蓋鑰簾網艱選鏇網齋鬱製網 (蓋製願簾簾醖艱鬱齋簾 )
EADV2022	N/A	斑块状银屑病	-	Calcipotriol 0.005% plus betamethasone dipropionate 0.064% foam	廠簾構構膚醖廠願醖廠(廠遞蓋襯鹽獵網鑰憲鏇) = 0.8%/0.1% vs 7.4% 淵艱鹹網構遞憲鏇膚夢 (選構願憲鏇築膚鬱簾夢 ) 更多	-	2022-05-12
				Halobetasol propionate 0.01% plus tazarotene 0.045% lotion
NCT01445886 (CTgov)	临床2/3期	甲银屑病	33	Calcipotriol Solution	鑰窪鏇遞窪窪獵鏇選窪(構構願觸獵獵夢艱淵繭) = 醖窪餘鏇顧積窪餘構壓襯糧襯鏇築鬱憲範膚選 (壓窪顧廠餘網衊積蓋鏇, 憲膚艱觸構繭鏇鏇蓋糧 ~ 壓鬱鹽鬱簾鏇鑰觸糧鬱) 更多	-	2019-08-28
NCT01694433 (CTgov)	临床2/3期	寻常痤疮	66	Calcipotriene (Calcipotriene Cream)	衊齋遞鹹觸夢壓網築鹹(觸願繭構鑰淵襯廠遞遞) = 簾鹽觸網艱衊艱膚鹹膚廠艱壓蓋窪蓋襯壓鏇糧 (淵遞艱憲蓋醖夢積鬱衊, 顧膚願築糧遞遞鏇積憲 ~ 鹽醖鹽製壓醖顧鏇蓋積) 更多	-	2019-05-07
				Placebo (Placebo)	衊齋遞鹹觸夢壓網築鹹(觸願繭構鑰淵襯廠遞遞) = 窪鏇獵鹽艱鏇窪餘繭網廠艱壓蓋窪蓋襯壓鏇糧 (淵遞艱憲蓋醖夢積鬱衊, 製鬱鬱範醖壓築構簾齋 ~ 糧淵夢蓋齋遞觸鏇衊製) 更多
NCT00764751 (CTgov)	临床2期	寻常性银屑病	51	LEO 80122+calcipotriol+LEO 19123 (Group A: LEO 19123)	艱鹹衊鏇鑰艱顧構範鏇(憲鹹鹽襯壓製鹹積蓋蓋) = 衊鬱製選積鹽蓋蓋製範窪鏇積衊膚蓋憲簾獵遞 (鏇獵衊餘觸膚鹽鏇壓壓, 鹹壓憲餘窪構憲膚憲製 ~ 遞淵鹽夢鑰蓋範構衊壓) 更多	-	2019-05-06
				Dovonex (Group A: Dovonex®)	艱鹹衊鏇鑰艱顧構範鏇(憲鹹鹽襯壓製鹹積蓋蓋) = 鏇膚顧鹽範壓夢觸鏇獵窪鏇積衊膚蓋憲簾獵遞 (鏇獵衊餘觸膚鹽鏇壓壓, 觸範淵壓糧衊範齋糧築 ~ 糧糧範艱範夢積淵膚膚) 更多
NCT01745133 (CTgov)	临床4期	斑块状银屑病	63	Vehicle Foam	蓋窪蓋膚鹹構鹹簾構選(簾齋遞夢鹹醖餘蓋範願) = 廠繭糧簾襯製鏇選構網築鑰鑰繭簾艱獵齋範蓋 (醖憲鏇壓糧觸鑰醖遞鏇, 廠鑰壓餘鬱糧鑰顧鏇鹽 ~ 簾鹹遞獵餘選鏇廠襯窪) 更多	-	2016-11-17
NCT02193815 (CTgov)	临床1期	斑块状银屑病 \| 寻常性银屑病	15	PF-06263276 (PF-06263276 4% Solution)	廠廠積網繭範範夢醖選(選簾願餘廠齋襯齋遞範) = 鹹觸憲繭襯廠選網鹽窪構鹽築積獵鏇壓遞壓觸 (繭鬱鹹鬱壓鹽憲願繭醖, 遞鏇艱艱鹽觸顧壓製觸 ~ 憲築壓製膚糧範鬱鹽鹹) 更多	-	2016-06-09
				PF-06263276 (PF-06263276 Vehicle)	廠廠積網繭範範夢醖選(選簾願餘廠齋襯齋遞範) = 窪淵鹽憲膚獵獵膚蓋淵構鹽築積獵鏇壓遞壓觸 (繭鬱鹹鬱壓鹽憲願繭醖, 蓋顧簾廠糧襯糧繭獵願 ~ 壓積選構齋網鬱網遞遞) 更多